证券代码：000710 证券简称：贝瑞基因 公告编号：2025-004 成都市贝瑞和康基因技术股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"、"本公司"） 股票于2025年3月3日、2025年3月4日连续两个交易日收盘价涨幅偏离值累计超 过20%。根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波 动。 二、公司关注并核实的相关情况 5、股票异常波动期间，控股股东、实际控制人及其一致行动人未买卖公司 股票； 6、公司不存在违反公平信息披露的情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所股票上市 规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、 意向、协议等；董事会也未获悉本公司有根据《深圳证券交易所股票上市规则》 等有关规定应予以披露而未披露的、对本公司股票及其衍生品种交易价格产生 较大影响的信息；公司前期披露的信息不存在需要更正、补充之处。 四、相 ...

好的，各位投资者上午好。这里是山西证券和贝睿金共同举办的电话会议上市公司交流， 主题是基因测序及 AI 大数据这里我线上的话是我们上市公司的董秘徐飞徐总主持的是山西 证券医药组的邓周宇副所长，我是山西证券魏云，同时在会的还有我们分析师杜鹏程以及 计算机的方文谦老师。接下来的话我们就正式开始。首先我们先请徐总先把公司的情况做 个简单的介绍，有请徐总。 发言人 2 0:00:45 好的，感谢各位投资者，也感谢山西证券的支持。首先就是我还是发几分钟，介绍一下北 基的一个整体情况。因为威睿确实这几年对外沟通的也比较少，我给大家简单介绍一下， 这个贝瑞基因我们主要是做基因检测工作，从事的这个领域主要是儿科、产科和遗传学科 的相关科室。比如大家众所周知的这项基因测序的 NIPT 的检测，这是贝瑞的一项核心业 务。这几年从经营情况来讲，大家可以先调整业绩，确实这几年一直是属于一个亏损的状 态。有这么几点原因。 一我们从前年开始一直在主推的是 NFTT 这个基础产品上的一个 plus 的一个升级产品， RGT 检测的是三种疾病的去检测，plus 产品就涵盖一百多种疾病的一个检测。它的价格也 是相对于 NIIT 的一个基础版产 ...

Group 1: Company Overview and Mission - Beirui Gene has focused on creating a new future in gene technology for 15 years, aiming to enhance human well-being through innovation [2] - The company operates in over 30 provinces and regions in China, as well as in Southeast Asia, the Middle East, and Australia, collaborating with over 2,000 hospitals [2] - Beirui has provided gene testing services to over 5 million individuals, alleviating economic burdens exceeding 100 billion yuan for society and families [2] Group 2: Genetic Testing and AI Integration - In the field of genetic disease testing, Beirui is developing a comprehensive diagnostic platform that offers various testing combinations for prenatal, pediatric, and adult genetic disease detection [2] - The company has built a vast medical knowledge graph by accumulating extensive experimental, research, and clinical data, which supports AI applications in healthcare [2][3] - The core value of AI in healthcare is to reconstruct the medical ecosystem, with plans to collaborate with top medical institutions for multi-omics data training [3] Group 3: Health Management Model and Data Utilization - Beirui's health management model is designed to provide rapid and accurate information on rare diseases, significantly improving decision-making efficiency [5] - The data lake contains over 10 million clinical diagnosis records and hundreds of billions of tokens, forming a knowledge graph with nearly 1 billion nodes and edges [5] - The company ensures data quality and security through strict compliance with national regulations, transforming individual data into group data for better analysis [6][7] Group 4: Collaboration and Future Projects - In January 2025, Beirui successfully delivered and tested the first batch of the Vega desktop long-read sequencing platform in collaboration with PacBio [7] - The company is accelerating the development and clinical registration of the Chinese version of the Vega CNDx model, aiming for overseas market approval [7]

Group 1: Company Overview and Market Position - Beirui Gene has been engaged in the gene sequencing industry for over 15 years, focusing on reproductive health, genetic disease testing, and technology services [2] - The company has accumulated a vast amount of diagnostic data, ranging from hundreds of megabytes to tens of gigabytes per sample, establishing a strong foundation for data processing [2] - The gene testing industry is transitioning from an algorithmic era to an intelligent era represented by large models, with significant attention on global market changes [2] Group 2: Data Accumulation and Infrastructure - The gene testing data center has surpassed the petabyte (PB) level in data storage, with over 100 million data points ready for internal research and analysis [3] - The company has built a comprehensive medical knowledge graph with over hundreds of millions of relationships and nearly 100 million nodes, ensuring high-quality and usable data [3] - The public data center and literature data center have also accumulated over 100 million data points combined, enriching the data dimensions available for analysis [3] Group 3: AI and Intelligent Tools - Beirui Gene has developed multiple proprietary algorithms and applications based on open-source large models, including genetic disease prediction and intelligent literature retrieval algorithms [4] - The company provides consulting services to over 2,000 hospitals and research institutions, enhancing clinical data interpretation efficiency [4] - The integration of AI algorithms has significantly improved report interpretation efficiency, increasing the output capacity of clinical reports [5] Group 4: Future Applications and Strategic Plans - The company plans to develop AI diagnostic, chronic disease management, and medical service segments for B-end clients, while also launching platforms for C-end clients [5] - Beirui Gene aims to accelerate the digital transformation of hospitals by promoting its intelligent products in alignment with national health strategies [2] - The company is strategically collaborating with major medical institutions to develop AI-driven big data solutions for molecular diagnosis and beyond [6] Group 5: Data Management and Security - The company has established unified data standards to address the challenges of data integration and ensure data accuracy and reliability [12] - A comprehensive data development framework has been created to assist clients in building frequency and variant databases, enhancing customer satisfaction and market competitiveness [14] - Data security measures include professional anonymization of private data, ensuring compliance while maximizing data utility [14]

成都市贝瑞和康基因技术股份有限公司 关于股票交易异常波动的公告 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-003 5、股票异常波动期间，控股股东、实际控制人及其一致行动人未买卖公司 股票； 6、公司不存在违反公平信息披露的情形。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"、"本公司"） 股票于2025年2月6日、2025年2月7日、2025年2月10日连续3个交易日收盘价涨 幅偏离值累计超过20%。根据《深圳证券交易所交易规则》的相关规定，属于 股票交易异常波动。 二、公司关注并核实的相关情况 根据相关规定的要求，公司及时进行了核查，并向公司控股股东和实际控制 人及其一致行动人进行了问询，现对有关核实情况说明如下： 1、公司前期所披露的信息，不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息； 3、公司已披露的经营情况、内外部经营环境未发生重大变化； 4、公司、控股股东和实际控制人及 ...

2025 年 2 月 5 日，公司通过淘宝网司法拍卖网络平台查询获悉，因案外人对拍 卖财产提出确有理由的异议，本场司法拍卖已撤回。 公司将持续关注本场司法拍卖及相关事项的进展情况，按照法律法规要求及时 履行信息披露义务，敬请投资者注意投资风险。 特此公告。 成都市贝瑞和康基因技术股份有限公司董事会 2025年2月5日 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-002 成都市贝瑞和康基因技术股份有限公司 关于控股股东所持公司部分股份司法拍卖撤回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 公司于 2024 年 12 月 28 日披露了《关于控股股东所持公司部分股份将被司法拍 卖的提示性公告》（公告编号：2024-056），成渝金融法院拟将公司控股股东高扬先 生持有的公司 16,600,000 股股票于 2025 年 2 月 6 日 10：00 时起至 2025 年 2 月 7 日 10：00 时止在淘宝网司法拍卖网络平台上进行公开拍卖（以下简称"本场司法拍卖"）。 1 ...

Financial Performance Expectations - The company expects a net loss attributable to shareholders of between 170 million and 250 million yuan for the fiscal year 2024, a reduction in loss of 41.48% to 60.21% compared to a loss of 427.2 million yuan in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 168 million to 248 million yuan, representing a decrease in loss of 40.51% to 59.70% compared to a loss of 416.8 million yuan last year [2]. - Basic earnings per share are expected to be a loss of 0.48 to 0.71 yuan per share, compared to a loss of 1.21 yuan per share in the previous year [2]. Revenue and Profitability Outlook - The company anticipates a slight decline in total operating revenue for the year, while the overall gross profit margin is expected to increase slightly [4]. Strategic Focus and Operational Improvements - The company is focusing on its core business and tightening operational strategies to enhance its competitive edge and improve sustainable operational capabilities [4]. - The company has conducted a comprehensive review and impairment testing of various assets, which has significantly impacted the net profit for the reporting period [4]. Financial Reporting and Audit Status - The financial data provided is preliminary and has not been audited, with the final figures to be disclosed in the 2024 annual report [5].

Core Viewpoint - Berry Genomics has announced the successful delivery and testing of the Vega platform, a desktop long-read sequencing platform developed in collaboration with Pacific Biosciences, aimed at enhancing genetic testing solutions for clinical needs in China and abroad [1][2]. Group 1: Product Development and Features - The Vega platform integrates the capabilities of PacBio's Revio system into a compact, medium-throughput desktop platform, utilizing HiFi technology to ensure data accuracy and turnaround time [1][2]. - The platform is designed to provide comprehensive solutions for various applications, including targeted sequencing, RNA sequencing, and small genome sequencing [1][2]. - The introduction of the Vega platform significantly improves the economic viability and accessibility of HiFi long-read sequencing, enabling more researchers to utilize this technology [2][3]. Group 2: Market Strategy and Clinical Applications - Berry Genomics plans to accelerate the development of customized genetic testing solutions based on the Vega platform to meet the growing clinical demands in both domestic and international markets [2][4]. - The company aims to enhance its market promotion efforts to facilitate the sales of the Vega platform, transitioning its business model from genetic testing services to upstream equipment and reagent sales [4][5]. - The Vega CNDx model is being developed to align with the characteristics of the Chinese population and clinical needs, contributing to the localization of sequencing platforms [5]. Group 3: Collaboration and Industry Position - PacBio's COO highlighted Berry Genomics' critical role in the development of the Vega platform, emphasizing the importance of their early testing and data accumulation from the Sequel II system [4]. - The collaboration is expected to deepen, leveraging Berry Genomics' extensive experience in the Chinese clinical market to tailor the Vega platform to meet local demands [4]. - Berry Genomics is positioning itself in the upstream core equipment market, recognizing sequencing instruments as a key component with high industry barriers [4].

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-057 成都市贝瑞和康基因技术股份有限公司 关于与专业投资机构共同投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、投资概述 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）全资子公司福建 贝瑞和康基因技术有限公司（以下简称"贝瑞和康"）与上海致凯资产管理有限公 司、福州新投创业投资有限公司、上海润达医疗科技股份有限公司、上海福凯瑞康 企业管理咨询合伙企业（有限合伙）共同签署《福州新投致凯瑞康创业投资基金合 伙企业（有限合伙）合伙协议》（以下简称"合伙协议"），共同投资设立福州新 投致凯瑞康创业投资基金合伙企业（有限合伙）（以下简称"合伙企业"），合伙 企业目标募资规模为人民币13,400万元，其中公司作为有限合伙人认缴出资2,680 万元，占合伙企业出资总额的20.00%。 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指 引第7号——交易与关联交易》《公司章程》等相关规定，本次对外投资事项无需 提交公司董事会及股东大会审议。 公司住所：上海市黄浦区茂名南 ...

关于控股股东所持公司部分股份将被司法拍卖的提示性公告 证券代码：000710 证券简称：贝瑞基因 公告编号：2024-056 成都市贝瑞和康基因技术股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次拍卖标的物为公司控股股东高扬先生持有的本公司 16,600,000 股股票， 占其持有公司股份的比例为 51.89%，占公司总股本的比例为 4.70%。上述将被司法 拍卖的股份为无限售流通股，均已被质押并司法再冻结。 2、目前该拍卖事项尚在公示阶段，后续可能涉及竞拍、缴款、法院执行法定程 序、股权变更、过户等环节，存在一定的不确定性，公司将根据进展情况，依法履行 相应的信息披露义务。本次拍卖事项存在导致公司控股股东发生变更的风险，敬请广 大投资者注意投资风险。 3、公司目前生产经营情况正常，该事项未对公司的生产经营及财务状况产生重 大不利影响，未对公司治理结构产生重大不利影响。 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"或"公司"）于 近日收到控股股东高扬先生发送的《成渝金融法院网络司法拍卖事项通知书》并通过 司法拍卖网 ...